GE HealthCare Technologies shares rose about 9% in premarket trading after the company reported second-quarter 2026 results that beat expectations, helped by stronger services revenue and a $129 million benefit from tariff refunds. Revenue reached $5.3 billion, exceeding estimates by $40 million, with organic growth of about 4% year-over-year. Services sales grew roughly 8% to $1.88 billion, above the $1.83 billion analysts had forecast, while product revenue rose about 5% to $3.42 billion, slightly missing the $3.45 billion consensus. The company posted a book-to-bill ratio of 1.15 times, ahead of the 1.06 projected, and its net income margin improved by 90 basis points to 10.6%. Adjusted earnings per share came in at $1.13, beating the consensus by $0.09, as net income climbed 15% to $561 million. GE HealthCare maintained its full-year guidance for adjusted EPS of $4.80 to $5.00 and organic revenue growth of 3% to 4%.
GE HealthCare Technologies Inc.Q2 earnings beat on services sales and tariff refunds, with EPS and revenue above estimates.
GE Aerospace